{
    "clinical_study": {
        "@rank": "6458", 
        "arm_group": [
            {
                "arm_group_label": "LY2940094", 
                "arm_group_type": "Experimental", 
                "description": "40 milligram (mg) LY2940094 oral tablet, once daily (QD) for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identically matched placebo oral tablet, once daily (QD) for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate a once daily (QD) 40 milligram (mg) oral dose\n      of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce\n      alcohol drinking in these participants. The study will last for 8 weeks."
        }, 
        "brief_title": "A Study of LY2940094 in Participants With Alcohol Dependency", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Present with alcohol dependence (AD) defined by the Diagnostic and Statistical Manual\n             of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR 303.9)\n\n          -  Must have 3 to 6 heavy drinking days per week as assessed by the Timeline Follow Back\n             (TLFB) scale at screening and baseline (heavy drinking is defined as greater than 4\n             drinks per day for females and greater than 5 drinks per day for males)\n\n          -  Have a body mass index (BMI) between 18 and 35 kilograms per square meter (kg/m^2)\n\n        Exclusion Criteria:\n\n          -  Have had prior seizures or other condition that would place the participant at\n             increased risk of seizures, and participants taking anticonvulsants for seizure\n             control\n\n          -  Have any other clinically significant medical condition or circumstance prior to\n             randomization that, in the opinion of the investigator, could affect participant\n             safety\n\n          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV)\n             Axis I criteria for a lifetime diagnosis of schizophrenia, schizoaffective disorder,\n             bipolar I disorder, or other psychoses"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798303", 
            "org_study_id": "14792", 
            "secondary_id": "I5J-MC-NOAD"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2940094", 
                "description": "Administered orally", 
                "intervention_name": "LY2940094", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to Week 8 in the Average Number of Drinks per Day (NDD) Measured Over 28 Days", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798303"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline to Week 8 in Gammaglutamyl Transferase (GGT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }, 
            {
                "measure": "Percentage of Heavy Drinking Days per Month", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 8"
            }, 
            {
                "measure": "Percentage of Days Abstinent per Month", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 8"
            }, 
            {
                "measure": "Percentage of Participants with No (0) Heavy Drinking Days per Month", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 8"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}